ONTOZRY™ (cenobamato) riceve il parere positivo del CHMP per l’uso come terapia aggiuntiva nelle crisi epilettiche a esordio focale non controllate negli adulti*
03. Februar 2021 05:57 ET
|
Arvelle Therapeutics
Il parere positivo del CHMP è un traguardo importante per Arvelle Therapeutics e per cenobamato Quando approvato, cenobamato rappresenterà una nuova speranza nell’aiutare i pazienti adulti affetti da...
ONTOZRY™ (cenobamato) ha recibido la opinión positiva del CHMP para el tratamiento concomitante de las crisis de inicio focal no controladas en adultos*
01. Februar 2021 07:26 ET
|
Arvelle Therapeutics
La opinión positiva del CHMP es un gran hito para Arvelle Therapeutics y cenobamato Una vez aprobado, cenobamato proporcionará a los pacientes adultos con epilepsia de inicio focal no controlada,...
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*
29. Januar 2021 12:20 ET
|
Arvelle Therapeutics
Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move...
Cenobamate als Medikament in Härtefallprogramm (CUP) für die Behandlung von arzneimittelresistenten fokal beginnenden Anfällen bei Erwachsenen aufgenommen
14. September 2020 01:00 ET
|
Arvelle Therapeutics
Cenobamate erreicht die Zulassung des Bundesinstituts für Arzneimittel und Medizinprodukte (BfArM) zum Arzneimittel-Härtefallprogramm für ein Jahr In Großbritannien wird cenobamate als...
Arvelle Announces Partnership with Durbin Across Europe
17. August 2020 01:00 ET
|
Arvelle Therapeutics
Arvelle Announces Partnership with Durbin Across Europe Zug, Switzerland, 17 August 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to...
Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults
11. August 2020 00:00 ET
|
Arvelle Therapeutics
PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme Milestone further supports the potential of cenobamate as an innovative...
Arvelle Announces Closing of Final Tranche of Series A Financing Round
26. Mai 2020 07:00 ET
|
Arvelle Therapeutics
Arvelle Announces Closing of Final Tranche of Series A Financing Round Brings the total financing to $207.8m Triggered by successful filing and validation of the MAA for cenobamate Zug,...
Arvelle Announces Closing of Final Tranche of Series A Financing Round
26. Mai 2020 02:00 ET
|
Arvelle Therapeutics
Arvelle Announces Closing of Final Tranche of Series A Financing Round Brings the total financing to $207.8m Triggered by successful filing and validation of the MAA for cenobamate Zug,...
Los resultados del último estudio publicado en la revista Neurology muestran que el tratamiento adyuvante con cenobamato mejoró significativamente el control de las crisis epilépticas en adultos(1)
26. Mai 2020 01:00 ET
|
Arvelle Therapeutics
El 28 % de los pacientes que recibieron cenobamato adyuvante, estuvieron libres de crisis (cero crisis) durante la fase de mantenimiento del estudio, frente al 9 % al que se le administró placebo.1 ...
Pubblicati su Neurology(1) i risultati di uno studio randomizzato che mostrano che la terapia aggiuntiva con cenobamato ha migliorato significativamente il controllo delle crisi negli adulti con crisi focali non controllate
26. Mai 2020 01:00 ET
|
Arvelle Therapeutics
Il 28% dei pazienti sottoposti a trattamento con cenobamato ha raggiunto l’assenza di crisi (zero crisi) nel corso della fase di mantenimento dello studio, rispetto al 9% dei pazienti trattati con...